RxDoctor Payments DataLook up a doctor →

Sarah Faber, NP

Psychiatric/Mental Health · Newport News, VANPI 1205313913

Payments from drug & device makers

$58,508in general payments, 2019–2025

Across 659 payments — averaging $88.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$48K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Supernus Pharmaceuticals, Inc.$1K
  • Johnson & Johnson$1K
  • Neurocrine Biosciences, Inc.$999
  • Otsuka America Pharmaceutical, Inc.$839
  • plus $5K from 23 others

What the payments were for

  • Speaking & faculty fees$41,52571%
  • Travel & lodging$3,9597%
  • Food & beverage$12,97822%
  • Education$460%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,508 in reported general payments places this provider in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.

See all psychiatric/mental health providers in Virginia

Medicare billing

Part B allowed, 2024
$20,726
Medicare patients
41
Services billed
214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Paliperidone ErPaliperidone13$8,995
Aripiprazole59$3,420
Desvenlafaxine Succinate ErDesvenlafaxine Succinate14$1,690
Buspirone Hcl43$1,095
Venlafaxine Hcl ErVenlafaxine Hcl12$1,080
Oxcarbazepine18$697
Mirtazapine27$651
Duloxetine Hcl13$636
Trazodone Hcl62$630
Lamotrigine36$563
Divalproex Sodium ErDivalproex Sodium12$471
Clonazepam76$458
Lurasidone Hcl14$387
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12$346
Prazosin Hcl19$299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$103$25523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.

Other psychiatric/mental health in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →